All In Biotech

Drug Trial Radar · NCT05650567

Study of M5049 in DM and PM Participants (NEPTUNIA)

A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Enpatoran in Dermatomyositis and Polymyositis Participants Receiving Standard of Care (NEPTUNIA)

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

20

Actual

Start

Jan 19, 2023

Primary completion

Jun 25, 2025

Study completion Jun 25, 2025

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany
First posted
Dec 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of orally administered M5049 in idiopathic inflammatory myopathies, specifically dermatomyositis (DM) and polymyositis (PM) participants for 24 weeks.

Conditions

  • Dermatomyositis
  • Polymyositis

Interventions

  • M5049 doseDrug

    Participants will receive film-coated tablets of M5049 dose orally, twice daily up to 24 weeks.

  • PlaceboDrug

    Participants will receive placebo matched to M5049 orally, twice daily up to 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double Blind Placebo Control Period (DBPC): American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Total Improvement Score (TIS) at Week 24Time frame: At Week 24 (end of DBPC period)
  2. DBPC Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)Time frame: Up to Week 26 (Safety follow up)
  3. DBPC Period: Number of Participants With Clinically Meaningful Changes From Baseline in Laboratory ParametersTime frame: Up to Week 26 (Safety follow up)
  4. DBPC Period: Number of Participants With Clinically Meaningful Changes From Baseline in Vital SignsTime frame: Up to Week 26 (Safety follow up)
  5. DBPC Period: Number of Participants With Clinically Meaningful Changes From Baseline in Electrocardiograms (ECG) ParametersTime frame: Up to Week 26 (Safety follow up)

Locations

31 sites in 7 countries. Site status is shown where the registry gives one.

  • Neuromuscular Research Center

    Phoenix, Arizona

  • HonorHealth Research Institute - Bob Bove Neuroscience Institute-Neuroscience Research

    Scottsdale, Arizona

  • Mayo Clinic Scottsdale (6365)

    Scottsdale, Arizona

  • Barbara Davis Center

    Aurora, Colorado

  • HMD Research LLC

    Orlando, Florida

  • Bolanos Clinical Research

    Pembroke Pines, Florida

  • Augusta University-Rheumatology

    Augusta, Georgia

  • Johns Hopkins University - Department of Medicine, Division of Rheumatology

    Baltimore, Maryland

  • University of Minnesota-Dermatology

    Minneapolis, Minnesota

  • University of Kansas Medical Center-Neuromuscular

    Kansas City, Missouri

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Austin Neuromuscular Center

    Austin, Texas

  • Nerve and Muscle Center of Texas-Clinical research

    Houston, Texas

  • Institute of Rheumatology - Rheumatology

    Prague, Czechia

  • Hippokration Hospital - 2nd Department of Medicine and Laboratory

    Athens, Greece

  • National and Kapodistrian University of Athens (Egnitio Hospital)

    Athens, Greece

  • University General Hospital of Larissa

    Larissa, Greece

  • Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco Di Catania (Vittorio Emanuele) - Reumatologia

    Catania, Italy

  • Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania

    Catania, Italy

  • Azienda Usl Toscana Centro

    Florence, Italy

  • Arcispedale S. Maria Nuova

    Reggio Emilia, Italy

  • Fondazione Policlinico Universitario A. Gemelli-IRCCS, UCSC - Scienze Mediche e Chirurgiche

    Rome, Italy

  • Instytut Reumatologii im. Eleonory Reicher - Department of Connective Tissue Diseases

    Warsaw, Poland

  • CHUAC - Complexo Hospitalario Universitario A Coruña - Rheumatology

    A Coruña, Spain

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario Ramon y Cajal, Madrid - Rheumatology Department

    Madrid, Spain

  • Doncaster Royal Infirmary (3466)

    Doncaster, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, United Kingdom

  • University College London Hospitals NHS Foundation Trust- Neuromuscular Diseases

    London, United Kingdom

  • Salford Royal Hospital, Barnes Clinical Research Facility

    Salford, United Kingdom

  • Royal Wolverhampton Hospitals (6493)

    Wolverhampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.